Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Rasmussen

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|February 23, 2020
Kick and kill for HIV latencySharon R Lewin, Thomas A Rasmussen
Current Opinion in HIV and AIDS|March 15, 2016
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?Thomas A Rasmussen, Sharon R Lewin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Toll-like Receptor 7 Agonists in People Living With HIV: Implications for Immunotherapeutic Strategies for an HIV CureThomas A Rasmussen, Sharon R Lewin
Molecular Medicine (Cambridge, Mass.)|March 23, 2011
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoirShay Matalon, Thomas A Rasmussen, Charles A Dinarello
Current Opinion in HIV and AIDS|August 2, 2021
Viral, inflammatory, and reservoir characteristics of posttreatment controllersJames McMahon, Sharon R Lewin, Thomas A Rasmussen
Ebiomedicine|February 5, 2022
Immune checkpoint blockade in HIVCeline Gubser, Chris Chiu, Sharon R Lewin, et al.
Journal of Virus Eradication|September 28, 2023
Immunomodulation with IL-7 and IL-15 in HIV-1 infectionJesper D Gunst, Nilu Goonetilleke, Thomas A Rasmussen, et al.
Current Opinion in HIV and AIDS|September 9, 2016
Cancer therapies in HIV cure researchThomas A Rasmussen, Jenny L Anderson, Fiona Wightman, et al.
The Lancet. HIV|January 15, 2016
Ethics of ART interruption after stem-cell transplantationJeremy Sugarman, Sharon R Lewin, Timothy J Henrich, et al.
Human Vaccines & Immunotherapeutics|April 9, 2013
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trialsThomas A Rasmussen, Martin Tolstrup, Anni Winckelmann, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|February 23, 2020
Kick and kill for HIV latencySharon R Lewin, Thomas A Rasmussen
Current Opinion in HIV and AIDS|March 15, 2016
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?Thomas A Rasmussen, Sharon R Lewin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Toll-like Receptor 7 Agonists in People Living With HIV: Implications for Immunotherapeutic Strategies for an HIV CureThomas A Rasmussen, Sharon R Lewin
Molecular Medicine (Cambridge, Mass.)|March 23, 2011
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoirShay Matalon, Thomas A Rasmussen, Charles A Dinarello
Current Opinion in HIV and AIDS|August 2, 2021
Viral, inflammatory, and reservoir characteristics of posttreatment controllersJames McMahon, Sharon R Lewin, Thomas A Rasmussen
Ebiomedicine|February 5, 2022
Immune checkpoint blockade in HIVCeline Gubser, Chris Chiu, Sharon R Lewin, et al.
Journal of Virus Eradication|September 28, 2023
Immunomodulation with IL-7 and IL-15 in HIV-1 infectionJesper D Gunst, Nilu Goonetilleke, Thomas A Rasmussen, et al.
Current Opinion in HIV and AIDS|September 9, 2016
Cancer therapies in HIV cure researchThomas A Rasmussen, Jenny L Anderson, Fiona Wightman, et al.
The Lancet. HIV|January 15, 2016
Ethics of ART interruption after stem-cell transplantationJeremy Sugarman, Sharon R Lewin, Timothy J Henrich, et al.
Human Vaccines & Immunotherapeutics|April 9, 2013
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trialsThomas A Rasmussen, Martin Tolstrup, Anni Winckelmann, et al.
Pageof 7